Literature DB >> 10871612

Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement.

P J Ceponis1, F Botelho, C D Richards, D M McKay.   

Abstract

Interleukins 4 and 13 can affect their target cells by activation of signal transducer and activator of transcription 6 (STAT 6) or phosphatidylinositol 3-kinase (PI3K). We examined the signal transduction events involved in IL-4 and IL-13 regulation of epithelial paracellular permeability using T84 cells, a model human colonic epithelium. T84 cells treated with IL-4 or IL-13 displayed virtually identical dose- and time-dependent STAT 6 activation as assessed by electrophoretic mobility shift assay (EMSA) and decreases in transepithelial resistance (TER). STAT 6 DNA binding activity was maximal in nuclear extracts 30 min after exposure to IL-4 or IL-13, and TER was maximally reduced by 24 h post-treatment. Pretreatment of epithelia with transcription factor decoys (phosphorothioated DNA oligonucleotides containing the STAT 6 binding site) dramatically reduced STAT 6 activation as detected by EMSA, but did not attenuate the TER reduction by IL-4 or IL-13. In contrast, although the PI3K inhibitors wortmannin and LY294002 did not affect IL-4 or IL-13 STAT 6 activation, they significantly inhibited the ability of either cytokine to lower TER. Thus, we provide evidence for PI3K as the major proximal signaling event in IL-4 and IL-13 regulation of TER and speculate that pharmacological targeting of enterocytic PI3K activity may represent a means to manipulate epithelial permeability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871612     DOI: 10.1074/jbc.M003516200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Regulation of intestinal epithelial permeability by tight junctions.

Authors:  Takuya Suzuki
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

2.  Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity.

Authors:  Christopher R Weber; David R Raleigh; Liping Su; Le Shen; Erika A Sullivan; Yingmin Wang; Jerrold R Turner
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 3.  Novel pathophysiological concepts of inflammatory bowel disease.

Authors:  Toshifumi Hibi; Haruhiko Ogata
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

Review 4.  Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness.

Authors:  Jessica A Clark; Craig M Coopersmith
Journal:  Shock       Date:  2007-10       Impact factor: 3.454

5.  Cytokine-mediated control of lipopolysaccharide-induced activation of small intestinal epithelial cells.

Authors:  Michael Lotz; Till König; Sandrine Ménard; Dominique Gütle; Christian Bogdan; Mathias W Hornef
Journal:  Immunology       Date:  2007-05-18       Impact factor: 7.397

Review 6.  Intestinal barrier function: molecular regulation and disease pathogenesis.

Authors:  Katherine R Groschwitz; Simon P Hogan
Journal:  J Allergy Clin Immunol       Date:  2009-07       Impact factor: 10.793

Review 7.  Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases.

Authors:  Oliver T Burton; Hans C Oettgen
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

Review 8.  Helminths and intestinal barrier function.

Authors:  Derek M McKay; Adam Shute; Fernando Lopes
Journal:  Tissue Barriers       Date:  2017-01-02

Review 9.  Cytokine responses and epithelial function in the intestinal mucosa.

Authors:  Joseph C Onyiah; Sean P Colgan
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

10.  Helicobacter pylori disrupts STAT1-mediated gamma interferon-induced signal transduction in epithelial cells.

Authors:  David J Mitchell; Hien Q Huynh; Peter J M Ceponis; Nicola L Jones; Philip M Sherman
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.